• Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
Skip to content
  • Facebook
  • Twitter
  • LinkedIn
  • Google News
BioPharma Media

BioPharma Media

Biopharmaceutical industry analysis.
 Credible, reliable, equitable.

  • Topic
    • COVID-19
    • New Drugs
    • Oncology
    • Metabolism
    • Neuroscience
    • Autoimmune Diseases
    • Infections
    • Rare/Orphan Diseases
    • Drug Safety
  • Section
    • Pharma & Biotech
    • Regulatory
    • Clinical Trials
    • Mergers & Acquisitions
    • Research
    • In the Pipeline
  • BioPharma Media
    • About Us
    • Our Team
    • Contact Us
    • Editorial Policy
    • Terms of Use
    • Privacy Policy

Astellas Pharma

Psoriasis.
Posted inAutoimmune Diseases, New Drugs, Regulatory

Sotyktu: Miracle Pill for Autoimmune Diseases

September 10, 2022September 13, 2022

Deucravacitinib by Bristol-Myers Squibb can help with psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, and systemic lupus erythematosus.

Pneumonia
Posted inInfections, New Drugs, Regulatory

Prevnar 20: New Pneumococcal Vaccine

November 13, 2021September 8, 2022

Pfizer has released an updated and improved version of Prevnar 13, a popular pneumococcal vaccine.

Pills.
Posted inOncology, Research

Not All Cancer Drugs Are Equally Useful

April 3, 2021September 8, 2022

Cheating out of ignorance, or Sleight of hand and no fraud. How pharmaceutical companies scam clinical trials.

BioPharma Media Logo
Biopharmaceutical industry analysis.
© 2023 BioPharma Media. Newspack by Automattic. The end-to-end solution. Privacy Policy
  • Facebook
  • Twitter
  • LinkedIn
  • Google News